Skip to main content

Genomic Sequencing Should Not be Part of the Standard of Care for Most Urologic Cancers.

There are currently few situations in which genomic testing is actionable for genitourinary tumors. Without clear indications or treatment paradigms, genomic sequencing cannot be recommended as a standard of care for genitourinary tumors.

Division: 
Citation: 

Abern, Michael R., John V. Dudinec, and Brant A. Inman. “Genomic Sequencing Should Not be Part of the Standard of Care for Most Urologic Cancers.” Eur Urol Focus, May 7, 2022. https://doi.org/10.1016/j.euf.2022.04.011.

Published Date: 
Saturday, May 7, 2022
Published In: 
European Urology Focus
PMID: 
35537938